Mainz, Germany | THE INDEPENDENT | Drug companies Pfizer and BioNTech have conclude Phase 3 Study of their COVID-19 Vaccine candidate BNT162b2 , whose primary efficacy analysis demonstrates it to be 95% effective against COVID-19 beginning 28 days after the first dose. According to a statement, efficacy was consistent across …
Read More »
Promising results – here’s what needs to happen next | ANNE MOORE | Preliminary data from the Pfizer/BioNTech COVID-19 vaccine trial suggests it provides 90% efficacy at preventing the disease. At the very least, this news will result in a large sigh of relief across the vaccine community. It signifies …
Read More »
Mainz, Germany | THE INDEPENDENT | German company BioNtech and Pfizer from the US have announced success in phase three study of an experimental vaccine to prevent COVID-19 infections. “Today is a great day for science and humanity. The first set of results from our Phase 3 COVID-19 vaccine …
Read More »
The Independent Uganda: You get the Truth we Pay the Price